Protein misfolding diseases: prospects of pharmacological treatment.

about

Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer.CDG Therapies: From Bench to Bedside.

P2860

Q47673940-EA96803F-0A85-45D1-85F0-565EA0CE3A16 Q52558429-EC730A58-146E-4163-A916-F4FF12131BA0

P2860

Protein misfolding diseases: prospects of pharmacological treatment.

Item

http://www.wikidata.org/entity/Q39410882

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Protein misfolding diseases: prospects of pharmacological treatment.

@en

Protein misfolding diseases: prospects of pharmacological treatment.

@nl

type

Item

label

Protein misfolding diseases: prospects of pharmacological treatment.

@en

Protein misfolding diseases: prospects of pharmacological treatment.

@nl

prefLabel

Protein misfolding diseases: prospects of pharmacological treatment.

@en

Protein misfolding diseases: prospects of pharmacological treatment.

@nl

P1476

Protein misfolding diseases: Prospects of pharmacological treatment

@en

P2093

A Gámez

http://www.w3.org/2001/XMLSchema#string

B Pérez

http://www.w3.org/2001/XMLSchema#string

C Pérez-Cerdá

http://www.w3.org/2001/XMLSchema#string

L R Desviat

http://www.w3.org/2001/XMLSchema#string

M Ugarte

http://www.w3.org/2001/XMLSchema#string

P Yuste-Checa

http://www.w3.org/2001/XMLSchema#string

S Brasil

http://www.w3.org/2001/XMLSchema#string

P2860

Human cystathionine β-synthase (CBS) contains two classes of binding sites for S-adenosylmethionine (SAM): complex regulation of CBS activity and stability by SAM

Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C

The FoldX web server: an online force field

An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis

Protein Folding and Mechanisms of Proteostasis

Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation

Road to ruin: targeting proteins for degradation in the endoplasmic reticulum

Pharmacological chaperoning: a primer on mechanism and pharmacology

Emerging novel concept of chaperone therapies for protein misfolding diseases

P304

450-458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CGE.13088

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Briso-Montiano

P577

2017-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28671287

http://www.w3.org/2001/XMLSchema#string

Protein misfolding diseases: prospects of pharmacological treatment.

about

P2860

P2860

Protein misfolding diseases: prospects of pharmacological treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698